Ken Fisher’s REGN Holdings & Trades

First Buy
Q3 2014
Duration Held
45 Quarters
Largest Add
Q1 2019
+4,264 Shares
Current Position
4,637 Shares
$2.61 M Value

Ken Fisher's REGN Position Overview

Ken Fisher (via Fisher Asset Management, LLC) currently holds 4,637 shares of Regeneron Pharmaceuticals, Inc. (REGN) worth $2.61 M, representing 0.00% of the portfolio. First purchased in 2014-Q3, this long-term strategic position has been held for 45 quarters.

Based on 13F filings since 2013, Ken Fisher has maintained a long-term strategic position in REGN, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2019, adding 4,264 shares. Largest reduction occurred in Q1 2025, reducing 1,537 shares.

Analysis based on 13F filings available since 2013 Q2

Ken Fisher's Regeneron Pharmaceuticals (REGN) Holding Value Over Time

Track share changes against reported price movement

Quarterly Regeneron Pharmaceuticals (REGN) Trades by Ken Fisher

Period Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q3 2014 +583 New Buy 583 $360.21
Q4 2014 -59 Reduce 10.12% 524 $410.31
Q1 2015 +10 Add 1.91% 534 $451.31
Q2 2015 +31 Add 5.81% 565 $509.73
Q3 2015 -61 Reduce 10.80% 504 $464.29
Q4 2015 +111 Add 22.02% 615 $543.09
Q1 2016 -2 Reduce 0.33% 613 $406.20
Q3 2016 +7 Add 1.14% 620 $401.61
Q4 2016 +95 Add 15.32% 715 $366.43
Q1 2017 +91 Add 12.73% 806 $387.10
Q2 2017 +605 Add 75.06% 1,411 $491.14
Q3 2017 +163 Add 11.55% 1,574 $447.27
Q4 2017 -109 Reduce 6.93% 1,465 $376.11
Q1 2018 -135 Reduce 9.22% 1,330 $344.36
Q2 2018 +250 Add 18.80% 1,580 $344.94
Q3 2018 -302 Reduce 19.11% 1,278 $403.76
Q4 2018 -14 Reduce 1.10% 1,264 $373.42
Q1 2019 +4,264 Add 337.34% 5,528 $410.64
Q2 2019 -99 Reduce 1.79% 5,429 $312.95
Q3 2019 +18 Add 0.33% 5,447 $277.40
Q4 2019 -159 Reduce 2.92% 5,288 $375.57
Q1 2020 -145 Reduce 2.74% 5,143 $488.24
Q2 2020 -2 Reduce 0.04% 5,141 $623.61
Q3 2020 +130 Add 2.53% 5,271 $559.86
Q4 2020 -44 Reduce 0.83% 5,227 $483.07
Q1 2021 -112 Reduce 2.14% 5,115 $473.12
Q2 2021 +44 Add 0.86% 5,159 $558.64
Q3 2021 -85 Reduce 1.65% 5,074 $605.24
Q4 2021 +142 Add 2.80% 5,216 $631.52
Q1 2022 -650 Reduce 12.46% 4,566 $698.42
Q2 2022 +3 Add 0.07% 4,569 $591.16
Q3 2022 +50 Add 1.09% 4,619 $688.89
Q4 2022 -13 Reduce 0.28% 4,606 $721.67
Q1 2023 -239 Reduce 5.19% 4,367 $821.67
Q2 2023 +1,001 Add 22.92% 5,368 $718.54
Q3 2023 -218 Reduce 4.06% 5,150 $823.10
Q4 2023 +472 Add 9.17% 5,622 $878.35
Q1 2024 +192 Add 3.42% 5,814 $962.54
Q2 2024 -149 Reduce 2.56% 5,665 $1051.07
Q3 2024 -608 Reduce 10.73% 5,057 $1051.32
Q4 2024 +833 Add 16.47% 5,890 $712.51
Q1 2025 -1,537 Reduce 26.10% 4,353 $634.37
Q3 2025 +284 Add 6.52% 4,637 $562.41

Ken Fisher's Regeneron Pharmaceuticals Investment FAQs

Ken Fisher first purchased Regeneron Pharmaceuticals, Inc. (REGN) in Q3 2014, acquiring 583 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Ken Fisher has held Regeneron Pharmaceuticals, Inc. (REGN) for 45 quarters since Q3 2014. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Ken Fisher's largest addition to Regeneron Pharmaceuticals, Inc. (REGN) was in Q1 2019, adding 5,528 shares worth $2.27 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

According to the latest 13F filing for Q3 2025, Ken Fisher's firm, Fisher Asset Management, LLC, owns 4,637 shares of Regeneron Pharmaceuticals, Inc. (REGN), valued at approximately $2.61 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

As of the Q3 2025 filing, Regeneron Pharmaceuticals, Inc. (REGN) represents approximately 0.00% of Ken Fisher's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Ken Fisher's peak holding in Regeneron Pharmaceuticals, Inc. (REGN) was 5,890 shares, as reported at the end of Q4 2024. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.